Hyungrok Choi

Hyungrok Choi
Patent Attorney

E-MAIL

hrchoi@seumip.com

TEL

+82.2.2135.5719

FAX

+82.2.2135.5720

Practice Area

  • Biotechnology, Healthcare, Pharmaceuticals, Chemistry, Materials, Clean energy

Qualification

  • 2020 Biotech Investment Analyst
  • 2017 Passed the Korean Patent Bar Examination

Education

  • 2010 KAIST (B.E., Chemical & Biomolecular Engineering)
  • 2005 Seoul Science High School

Hyungrok works at SEUM IP on patent matters in the fields of protein medicines, genetic diagnosis, medical devices and digital healthcare.  Danny filed and prosecuted patent applications, dealt with patent litigations at KIM & CHANG on behalf of global companies, and built patent portfolios for many Korean domestic companies at Sangsang Patent & Law Firm and IPCJ Patent & Law Firm.

Experience
  • 2024-present
    SEUM IP
  • 2023-24
    IPCJ Patent & Law Firm
  • 2022-23
    Sangsang Patent & Law Firm
  • 2018-22
    KIM & CHANG
Representative Matters

[1] Handling patent disputes in the fields of biotech

  • Represented global genetic diagnosis companies in patent infringement lawsuits and patent scope confirmation trials
  • Provided advice in international arbitration between a domestic genetic diagnosis kit manufacturer and an overseas company


[2] Performing patent work for global biotech, pharmaceutical and chemical companies

  • Represented global biopharmaceutical companies such as Pfizer, Biogen, Regeneron and Amgen in patent filing and prosecution 
  • Represented global chemical companies such as BASF, DuPont, Merck, Toray and Sumitomo in patent filing and prosecution
  • Represented global pharmaceutical companies related to Patent Term Extension (PTE) and Patent Listing Application (PLA) of commercially available drugs


[3] Providing strategic advice on M&A regulations to emerging biotech companies

  • Provided advice on regulations regarding the acquisition of a domestic genetic diagnostic company by a global healthcare company
  • Assisted Korean emerging biotech company to prove that their technology does not fall on the export control list established by Korean government


[4] Assisting startups to do IP-driven growth

  • Built patents portfolio for overseas licensing of new drug biotech startups
  • Conducted FTO analysis in bio platfrom technology for biotech startups
Publications and Activities
  • 2019-present Member of the Korea Patent Attorneys Association (KPAA)
Language
  • Korean, English